BiotechTube

Daptomycin for Injection

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bacteremia

Conditions

Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious

Trial Timeline

Dec 6, 2018 → Apr 7, 2020

NCT ID
NCT03643952

About Daptomycin for Injection

Daptomycin for Injection is a phase 2 stage product being developed by Merck for Bacteremia. The current trial status is completed. This product is registered under clinical trial identifier NCT03643952. Target conditions include Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious.

What happened to similar drugs?

2 of 5 similar drugs in Bacteremia were approved

Approved (2) Terminated (3) Active (1)
✅Daptomycin + ComparatorMerckApproved
✅Vancomycin + DaptomycinMerckApproved
❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3
❌Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
🔄Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03643952Phase 2Completed

Competing Products

9 competing products in Bacteremia

See all competitors
ProductCompanyStageHype Score
Daptomycin + ComparatorMerckApproved
43
Vancomycin + DaptomycinMerckApproved
35
Ceftolozane-Tazobactam + MeropenemMerckPhase 3
32
Cefazolin IV + Linezolid IV + Vancomycin (IV)PfizerPhase 3
32
Aurexis®Bristol Myers SquibbPhase 2
35
ceftobiprole medocarilBasilea PharmaceuticaPhase 2
21
Ceftobiprole medocaril + DaptomycinBasilea PharmaceuticaPhase 3
34
AP-SA02Armata PharmaceuticalsPhase 1/2
22
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIXBiotechPhase 1/2
22